-
Sector Analysis
KOL Perspectives: Voclosporin Data in Lupus Nephritis
› This KOL Insight briefing focuses on perceptions of voclosporin data in lupus nephritis presented at EULAR 2017
-
Product Insights
Myasthenia Gravis Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Myasthenia Gravis Global Clinical Trials Review, H1, 2018" provides an overview of Myasthenia Gravis clinical trials scenario. This report provides top line data relating to the clinical trials on Myasthenia Gravis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Consumer Insights
KOL Perspectives: Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis
› This KOL Insight briefing focuses on KOL opinions of the safety of JAK inhibitors in rheumatoid arthritis (RA)
-
Consumer Insights
KOL Perspectives: Mid-to-Late Stage Pipeline Therapies in Lupus
› This KOL Insight briefing focuses on opinions of mid- to late-stage pipeline therapies in lupus
-
Consumer Insights
KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis
› This KOL Insight briefing focuses on perceptions of IL-6 inhibitors in rheumatoid arthritis (RA)
-
Sector Analysis
Myasthenia Gravis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Myasthenia Gravis (MG) is a relatively rare, acquired, chronic, autoimmune neuromuscular disease caused by an antibody-mediated blockade at the neuromuscular transmission, resulting in skeletal muscle weakness and rapid muscle fatigue. In many adults with MG, the thymus gland remains large. People with the disease typically have clusters of immune cells in their thymus gland and may develop thymomas (tumors of the thymus gland). The myasthenia gravis marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, pricing...
-
Product Insights
Myasthenia Gravis Disease - Global Clinical Trials Review, H1, 2021
GlobalData's clinical trial report, “Myasthenia Gravis Disease - Global Clinical Trials Review, H1, 2021" provides an overview of Myasthenia Gravis Clinical trials scenario. This report provides top line data relating to the clinical trials on Myasthenia Gravis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also...
-
Product Insights
Sarcoidosis Disease - Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Sarcoidosis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Sarcoidosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Sarcoidosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Sector Analysis
Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2029
The rheumatoid arthritis (RA) market is expected to grow from $26.2bn in 2019 to $29.1bn in 2029 across the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 1.0%. This report discusses that although the RA market is expected to grow during the forecast period, this growth will be stymied by erosion from biosimilars. Rose Joachim, PhD, Senior Immunology Analyst at GlobalData, explains: “Between 2019 and 2029, there will be modest growth in the RA market. Growth will...
-
Sector Analysis
Psoriasis - Competitive Landscape in 2020
Interleukin and tumor necrosis factor inhibitors are the major focus of drug developers. There are 350 drugs in the pipeline, 89% 0f which are in early-stage. Big pharma dominates R&D in this indication. Addition of several high-priced therapies are expected to drive the market growth, but emergence of biosimilars to all the marketed brands is expected to act as a strong barrier to market growth.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.